59 results about "Rectal Adenocarcinoma" patented technology

The invention discloses a serum miRNAs specific expression profile for early colonic adenocarcinoma and rectal adenocarcinoma, which is formed by up-regulated expressed miR-19a-3p, miR-92a-3p and miR223-3p and down-regulated expressed miR422a. A reverse transcription primer and a detection primer, which are shown as SEQ ID NO: 1-9, of the miRNAs are specifically expressed in the serum miRNAs specific expression profile for the early colonic adenocarcinoma and rectal adenocarcinoma. The invention also provides a serum miRNAs disgnosis model for the early colonic adenocarcinoma and rectal adenocarcinoma, the following formula of logit(P=CAC)=0.4424-0.0092*(miR-19a-3p)-0.0368*(miR-92a-3p)-0.0517*(miR-223-3p)+0.2439*(miR-422a) is used for calculation and for the diagnosis on the early colonic adenocarcinoma and rectal adenocarcinoma, the diagnosis efficiency of the serum miRNAs model on the colonic adenocarcinoma and rectal adenocarcinoma is higher and is higher than that of the traditional tumor marker CEA through ROC (Receiver Operating Characteristic) curve analysis, and the model can used for the diagnosis on the early colonic adenocarcinoma and rectal adenocarcinoma patient (TNM I/II period).

The invention relates to a new application of furanodiene in pharmacy field, in particular to the application of the furanodiene in the preparation of medicines for treating the various malignant tumor diseases such as oophoroma, cervical carcinoma, gastric cancer, liver cancer, leucocythemia, lung cancer, oral carcinoma (epidermoid carcinoma), rectal adenocarcinoma, mammary cancer, malignant melanoma, colonic adenocarcinoma, nasopharyngeal carcinoma, carcinoma of prostate, etc. The invention also relates to the application of the furanodiene in the preparation of drugs for treating the diseases caused by herpesvirus, influenza virus and hepatitis B virus.

The invention discloses a marker SLC26A9 for diagnosing and treating rectal adenocarcinoma. The experiment proves that the SLC26A9 is highly expressed in metastasis rectal adenocarcinoma tissues. The expression level of the SLC26A9 can be detected to predict the risk of rectal adenocarcinoma metastasis, diagnose the metastasis of the rectal adenocarcinoma and judge whether rectal adenocarcinoma relapses. The invention also discloses application of the SLC26A9 gene in preparing drugs for inhibiting/preventing metastasis of rectal adenocarcinoma.

The invention discloses applications of FAM176A gene in diagnosis and treatment for rectum adenocarcinoma. The experiment proves that the FAM176A gene is in low expression in the tissue of the patient suffering from rectum adenocarcinoma; and the adding of the expression of FAM176A can inhibit the proliferation of rectum adenocarcinoma cells and promote the apoptosis of the rectum adenocarcinoma cells. According to the invention, a diagnosis means for the rectum adenocarcinoma is discovered, and meanwhile, a novel target spot is provided for the gene therapy of the rectum adenocarcinoma.

The invention discloses a genetic marker-MANBA associated with rectal adenocarcinoma and further discloses applications of the MANBA gene in production of products for prejudging risk of rectal adenocarcinoma metastasis, diagnosing transferring of rectal adenocarcinoma and judging recurrence of rectal adenocarcinoma. Meanwhile, the invention discloses an application of the MANBA gene in production of drugs for inhibiting/preventing rectal adenocarcinoma from being transferred.

The present invention discloses methods and tools for reliably detecting the presence of adenocarcinoma cells in a patient, at the genetic level. The present invention fine-maps the regions of chromosomal aberrations linked to progression of adenomas into adenocarcinoma cells and provides methods and tools for detection based thereon.

The invention discloses a molecular marker for rectal adenocarcinoma diagnosis and treatment. The molecular mark is a SHROOM4 gene which is in a low-expression mode in tissue of a patient with rectal adenocarcinoma, and rectal adenocarcinoma apoptosis can be promoted by improving expression of SHROOM4. According to the molecular marker for the rectal adenocarcinoma diagnosis and treatment, sensibility and specificity of the rectal adenocarcinoma diagnosis are greatly improved, and meanwhile a new target site is provided for a gene therapy of the rectal adenocarcinoma.

The invention relates to an application of a compound marsdenia tenacissima glycoside B which is extracted and separated from natural plant marsdenia tenacissima in the preparation of a drug for remedying tumour diseases including various malignant tumour diseases, such as ovary cancer, stomach cancer, liver cancer, leucocythemia, lung cancer, oral epidermoid carcinoma, rectal adenocarcinoma, breast cancer, malignant melanocarcinoma, colon adenocarcinoma, nasopharyngeal carcinoma, prostate cancer, etc. The invention also relates to a preparation technology of the marsdenia tenacissima glycoside B. After using water extraction and alcohol sedimentation, the invention uses an innovative chloroform extraction and aether sedimentation technology by chloroform extraction and also creatively adding aether, thereby reducing the content of impurity in extract obviously, and the marsdenia tenacissima glycoside B with high purity can be obtained just by silica gel column separation at a time. The method has high yield and simple operation, does not require a preparation type precision instrument of high performance liquid phase and other similar instruments and is closer to the requirement of the industrialized production.

The invention discloses a matrine pyrimidine derivative, and a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. The matrine pyrimidine derivative is a compound represented by a general formula (I) shown in the specification, or a compound represented by a general formula (II) shown in the specification. The matrine pyrimidine derivative disclosed by the invention has certain inhibitory activity on human tumor cells (human prostate cancer cells DU-145, human non-small cell lung cancer cells A549, human colorectal adenocarcinoma cells HCT15 and human cervical carcinoma cells HeLa), so that proliferation and differentiation of the tumor cells can be inhibited, and a new thought is provided for research and development of anti-tumor drugs; and the preparation method disclosed by the invention is simple, convenient and controllable, and the obtained product is high in yield and extremely high in purity.

The present invention relates generally to a method of determining one or more probabilities of respective classifications of a neoplasm into one or more neoplastic categories. More particularly, the present invention relates to a method of determining the probability of classification of a large intestine neoplasm into one or more categories selected from adenoma, stage I, stage II, stage III or stage IV by screening for changes to the methylation levels of a panel of gene markers, including BCAT1, IKZF1, IRF4, GRASP and/or CAHM. The method of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinosis.

The invention discloses application of long-chain non-coding RNA in tumors and specifically discloses application of LOC105378728 in the diagnosis and treatment of rectal adenocarcinoma. LOC105378728is up-regulated in patients with rectal adenocarcinoma, and whether a subject has rectal adenocarcinoma can be judged by detecting the expression level of LOC105378728.

The present invention relates generally to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset or predisposition to the onset of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset and/or progression of a large intestine or breast neoplasm, such as an adenoma or adenocarcinoma. The DNA methylation status of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal or breast neoplasms, such as colorectal or breast adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in DNA methylation of one or more nucleic acid molecules. The nucleic acid molecules used for diagnostics in the present invention are sequences from LOC 100526820, subsequently named CAHM (colorectal adenocarcinoma hypermethylated).

The invention discloses a structural simplification of a natural product 4-O-methyl saucerneol of lignans, and a preparation method, a pharmaceutical composition and application thereof. The inventionspecifically relates to a compound as shown in a formula (I) or an isomer thereof and a pharmaceutically acceptable salt thereof, and a preparation meathod of the compounds. The novel pharmaceuticalcomposition comprises an effective dose of the compound as shown in the formula (I) and a pharmaceutically acceptable carrier. The invention also discloses application of the compounds to prepare a medicament for the preparation, prevention and/or treatment of tumors, wherein the tumors includes neural glioblastoma, melanoma, gastric cancer, lung cancer, breast cancer, kidney cancer, liver cancer,oral epidermal cancer, cervical cancer, ovarian cancer, pancreatic cancer, prostatic cancer, colon cancer and rectal adenocarcinoma.

The invention discloses an application of magnolin in resisting colorectal cancer. Magnolin significantly inhibits the growth and proliferation of human colorectal cancer cells and human colorectal adenocarcinoma cells, significantly inhibits the growth of human colorectal cancer, and significantly inhibits the cell cycle of human colorectal cancer; magnolin promotes the autophagy of human colorectal cancer cells and human colorectal cancer. By blocking LIF/Stat3/Mcl-1 pathways, magnolin can promote the autophagy of the colorectal cancer cells and colorectal cancer, inhibits the proliferationof the colorectal cancer cells and blocks the period of the colorectal cancer cells. Magnolin has the activity of resisting human colorectal cancer cells and human colorectal cancer, and can be used for preparing products for resisting colorectal cancer or resisting the colorectal cancer cells.

The invention discloses a gene HRNBP3 and new application of an expression product of the gene HRNBP3 in diseases, and particularly relates to the gene HRNBP3 and application of the expression product of the gene HRNBP3 in diagnosis and treatment of the rectal adenocarcinoma. The invention further discloses application of the gene HRNBP3 in preparation of a product for diagnosing the rectal adenocarcinoma, and meanwhile discloses application of the gene HRNBP3 in preparation of medicine for treating the rectal adenocarcinoma.